Treatment is not always warranted for older men with prostate cancer and a short life expectancy, Yale School of Medicine researchers report in the Feb. 27 Archives of Internal Medicine.
- Careers - 08:05 Penn State conference addresses life beyond classroom for people with autism
- Arts - Jul 29 Penn Alumnus, House Dean Chris Donovan Champions His Love of Cinema
- Medicine - Jul 29 Yale’s Roy Herbst to be featured on Times Square billboard
- Environmental Sciences - Jul 29 Huge waves measured for first time in Arctic Ocean
- Medicine - Jul 29 Health Sciences News Digest 7.29.2014
- Medicine - Jul 29 Team Makes Cancer Glow to Improve Surgical Outcomes
- Mechanical Engineering - Jul 29 Researchers seek ’Holy Grail’ in battery design
- Medicine - Jul 29 Task force, other efforts addressing sexual assault move ahead at Stanford
- Life Sciences - Jul 29 Q&A: Stanford’s Carla Shatz on fostering interdisciplinary collaboration
- Computer Science - Jul 29 Vision- correcting display makes reading glasses so yesterday
- Medicine - Jul 29 Diet Affects Men’s and Women’s Gut Microbes Differently
- Business - Jul 29 Harper Court sale allows University to ensure continuing community benefits
Prostate cancer treatment overused in some older patients
"Treatment can do more harm than good in some instances," said senior author on the study Cary Gross , associate professor of internal medicine at Yale School of Medicine. "Among men who are older and have less aggressive forms of prostate cancer, their cancer is unlikely to progress or cause them harm in their remaining years."
Gross and his team analyzed nine years of Medicare data and found that over the past decade, there has been a trend towards higher use of curative treatment for prostate cancer among men with certain types of tumors and a short life expectancy. The study included 39,270 patients between the ages of 67 and older.
These results suggest that cancer treatment was increasingly aggressive in patients who had the lowest likelihood of seeing clinical benefits, Gross said, noting that while not treating potentially fatal cancer can reflect poor-quality care, aggressively managing disease that is unlikely to progress puts patients at risk for complications and increases costs without medical benefits.
"We found that the percentage of men who received treatment for their prostate cancer treatments increased over time from 61.2% to 67.6% from 1998 through 2007," said Gross, who is a member of Yale Cancer Center. "However, we were surprised to find that the biggest increase was among men with moderate-risk prostate cancer who had the shortest life expectancy. On the other hand, cancer treatment decreased among men with low-risk tumors and longer life expectancy."
Treating patients with shorter life expectancy may add costs or complications without contributing to quality of life, he said. The National Comprehensive Cancer Network practice guidelines in oncology recommend actively monitoring patients as an alternative to medication for patients with less aggressive tumor types and shorter life expectancies.
Gross said that the use of cancer therapies should be guided by clinical evidence and patient preferences. "Future work should explore how better to incorporate both cancer characteristics and patient life expectancy into decision making," said Gross.
Other authors on the study included Ann c. Raldow, M.D., Carolyn J. Presley, M.D., James B. Yu, M.D., Richa Sharma, Pamela R. Soulos, Jessica B. Long, and Danil V. Makarov, M.D.
The National Cancer Institute and the James G. Hirsch Medical Student Research Fellowship funded the study.
Citation: Arch. Inter. Med. Vol. 172, No. 4 (February 27, 2012)
Last job offers
- Earth Sciences - 30.7
- Medicine - 29.7
Assistant or Associate Professor
- Pedagogy - 29.7
Open Rank Faculty Positions in Quantitative Methods
- Administration - 28.7
- Architecture - 26.7
Associate Professor / Professor
- Architecture - 26.7
Associate Professor/ Professor
- Social Sciences - 26.7
Assistant Professor - Social Neuroscience
- Pedagogy - 26.7